Clinical Trials Logo

Clinical Trial Summary

This study evaluates the effects of 40 mg of b-2Cool, a food supplement rich in native type-II collagen, on healthy adults with joint discomfort. Half of the participants will receive the b-2Cool containing supplement while the other half will receive a placebo pill.


Clinical Trial Description

Previous studies had shown the efficacy of the intake of native collagen to relieve pain in healthy patients with joint discomfort.

Native collagen is detected in the gut's Peyer's patches and, thanks to a mechanism known as oral tolerisation, reduces the autoimmune attack to joints' collagen improving joint function and pain.

Oral tolerance consists of two phases of immune response: the maintenance of homeostasis and the suppression of immune responses mediated by Ag-specific regulatory T cells. T-cells detect the epitopes of type-II collagen in the gut and suppress the immune response against bodily type-II collagen. Then, these regulatory T cells generated in the gut are presumed to migrate to a local microenvironment where a protein analogous to the orally dosed antigen resides, in this case type-II collagen. Upon reactivation in a new microenvironment, regulatory cells will suppress ongoing inflammation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02843620
Study type Interventional
Source Bioiberica
Contact
Status Withdrawn
Phase N/A
Start date July 2018
Completion date July 2018

See also
  Status Clinical Trial Phase
Completed NCT04955353 - Efficacy of a Hydrolyzed Chicken Collagen Type II in Alleviating Joint Discomfort N/A